| Dr Brian Samuel Smith, MD | |
|
415 Broad St, Suite 410, Kingsport, TN 37660-4263 | |
| (423) 439-2737 | |
| Not Available |
| Full Name | Dr Brian Samuel Smith |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 17 Years |
| Location | 415 Broad St, Kingsport, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629298757 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 48138 (Tennessee) | Secondary |
| 207P00000X | Emergency Medicine | 0101256622 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wellmont Bristol Regional Medical Center | Bristol, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tri-cities Regional Emergency Physicians, Pc | 3678859477 | 129 |
News Archive
Eating rye comes with a variety of health benefits. A new study from the University of Eastern Finland now shows that both lactic acid bacteria and gut bacteria contribute to the health benefits of rye.
Researchers in Germany have finished the first complete analysis of the "molecular machines" in one of biology's most important model organisms: S. cerevisiae (baker's yeast). The study from the biotechnology company Cellzome, in collaboration with the European Molecular Biology Laboratory (EMBL), appears in this week's online edition of Nature.
Scientists from the EPFL and the University of Geneva have discovered a genetic mechanism that defines the shape of our members in which, surprisingly, genes play only a secondary role. The research published in Cell, online the 23rd of November, shows the mechanism is found in a DNA sequence that was thought, incorrectly, to play no role.
Celtaxsys, Inc., a clinical stage pharmaceutical development company focusing on anti-inflammatory therapeutics, including those with rare and orphan inflammatory disease indications, announced today that it has gained clearance from the U.S. Food and Drug Administration to begin a Phase 2 clinical trial of its flagship drug candidate, acebilustat (CTX-4430), in adult CF patients in the US.
› Verified 9 days ago
| Entity Name | Northeast Tennessee Emergency Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467427138 PECOS PAC ID: 7517911712 Enrollment ID: O20050310000431 |
News Archive
Eating rye comes with a variety of health benefits. A new study from the University of Eastern Finland now shows that both lactic acid bacteria and gut bacteria contribute to the health benefits of rye.
Researchers in Germany have finished the first complete analysis of the "molecular machines" in one of biology's most important model organisms: S. cerevisiae (baker's yeast). The study from the biotechnology company Cellzome, in collaboration with the European Molecular Biology Laboratory (EMBL), appears in this week's online edition of Nature.
Scientists from the EPFL and the University of Geneva have discovered a genetic mechanism that defines the shape of our members in which, surprisingly, genes play only a secondary role. The research published in Cell, online the 23rd of November, shows the mechanism is found in a DNA sequence that was thought, incorrectly, to play no role.
Celtaxsys, Inc., a clinical stage pharmaceutical development company focusing on anti-inflammatory therapeutics, including those with rare and orphan inflammatory disease indications, announced today that it has gained clearance from the U.S. Food and Drug Administration to begin a Phase 2 clinical trial of its flagship drug candidate, acebilustat (CTX-4430), in adult CF patients in the US.
› Verified 9 days ago
| Entity Name | Wellmont Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780986257 PECOS PAC ID: 8123291739 Enrollment ID: O20111026000909 |
News Archive
Eating rye comes with a variety of health benefits. A new study from the University of Eastern Finland now shows that both lactic acid bacteria and gut bacteria contribute to the health benefits of rye.
Researchers in Germany have finished the first complete analysis of the "molecular machines" in one of biology's most important model organisms: S. cerevisiae (baker's yeast). The study from the biotechnology company Cellzome, in collaboration with the European Molecular Biology Laboratory (EMBL), appears in this week's online edition of Nature.
Scientists from the EPFL and the University of Geneva have discovered a genetic mechanism that defines the shape of our members in which, surprisingly, genes play only a secondary role. The research published in Cell, online the 23rd of November, shows the mechanism is found in a DNA sequence that was thought, incorrectly, to play no role.
Celtaxsys, Inc., a clinical stage pharmaceutical development company focusing on anti-inflammatory therapeutics, including those with rare and orphan inflammatory disease indications, announced today that it has gained clearance from the U.S. Food and Drug Administration to begin a Phase 2 clinical trial of its flagship drug candidate, acebilustat (CTX-4430), in adult CF patients in the US.
› Verified 9 days ago
| Entity Name | Tri-cities Regional Emergency Physicians, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063950046 PECOS PAC ID: 3678859477 Enrollment ID: O20170410002399 |
News Archive
Eating rye comes with a variety of health benefits. A new study from the University of Eastern Finland now shows that both lactic acid bacteria and gut bacteria contribute to the health benefits of rye.
Researchers in Germany have finished the first complete analysis of the "molecular machines" in one of biology's most important model organisms: S. cerevisiae (baker's yeast). The study from the biotechnology company Cellzome, in collaboration with the European Molecular Biology Laboratory (EMBL), appears in this week's online edition of Nature.
Scientists from the EPFL and the University of Geneva have discovered a genetic mechanism that defines the shape of our members in which, surprisingly, genes play only a secondary role. The research published in Cell, online the 23rd of November, shows the mechanism is found in a DNA sequence that was thought, incorrectly, to play no role.
Celtaxsys, Inc., a clinical stage pharmaceutical development company focusing on anti-inflammatory therapeutics, including those with rare and orphan inflammatory disease indications, announced today that it has gained clearance from the U.S. Food and Drug Administration to begin a Phase 2 clinical trial of its flagship drug candidate, acebilustat (CTX-4430), in adult CF patients in the US.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brian Samuel Smith, MD 415 Broad St, Suite 410, Kingsport, TN 37660-4263 Ph: (423) 239-9737 | Dr Brian Samuel Smith, MD 415 Broad St, Suite 410, Kingsport, TN 37660-4263 Ph: (423) 439-2737 |
News Archive
Eating rye comes with a variety of health benefits. A new study from the University of Eastern Finland now shows that both lactic acid bacteria and gut bacteria contribute to the health benefits of rye.
Researchers in Germany have finished the first complete analysis of the "molecular machines" in one of biology's most important model organisms: S. cerevisiae (baker's yeast). The study from the biotechnology company Cellzome, in collaboration with the European Molecular Biology Laboratory (EMBL), appears in this week's online edition of Nature.
Scientists from the EPFL and the University of Geneva have discovered a genetic mechanism that defines the shape of our members in which, surprisingly, genes play only a secondary role. The research published in Cell, online the 23rd of November, shows the mechanism is found in a DNA sequence that was thought, incorrectly, to play no role.
Celtaxsys, Inc., a clinical stage pharmaceutical development company focusing on anti-inflammatory therapeutics, including those with rare and orphan inflammatory disease indications, announced today that it has gained clearance from the U.S. Food and Drug Administration to begin a Phase 2 clinical trial of its flagship drug candidate, acebilustat (CTX-4430), in adult CF patients in the US.
› Verified 9 days ago
Dr. James Henry Burleson, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2000 Brookside Dr, Indian Path Hospital, Kingsport, TN 37660 Phone: 423-857-7870 Fax: 423-857-7872 | |
William D Hudson, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 130 W Ravine Rd, Kingsport, TN 37662 Phone: 423-224-4000 | |
Mrs. Susan Watts Jeansonne, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2002 Brookside Dr, Suite 200, Kingsport, TN 37660 Phone: 423-224-3933 Fax: 423-224-3934 | |
Dr. Jeffrey Stayer, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 130 W Ravine Rd, Kingsport, TN 37660 Phone: 423-239-9737 | |
Dr. Renee May Sayson Miranda, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 102 E Ravine Rd, Kingsport, TN 37660 Phone: 423-245-9600 Fax: 423-245-9634 | |
William E Devens Jr., MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 130 W Ravine Rd, Kingsport, TN 37662 Phone: 423-224-4000 | |
Dr. Tunga Trishul Reddy, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 415 Broad St, Suite 410, Kingsport, TN 37660 Phone: 423-747-1240 |